Bioinformatics Articles

  1. Annual Reflections And Predictions From The Editors' Roundtable 1/6/2026

    Understanding the full scope of the life science industry has never been more critical. Ray Dogum, Chief Editor of Drug Discovery Online, joins the Life Science Connect Editors’ Roundtable on a special episode of Better Biopharma podcast.

  2. 2025's Top 5 Drug Discovery Highlights And How To Stay Ahead In 2026 12/15/2025

    Drug Discovery Online's 2025 Top 5 most consequential shifts affecting this rapidly evolving field, including NAMs, AI, Individualized Therapies, Innovating China, and Early-stage Funding Volatility.

  3. From Funding Gaps to AI Frontiers: Insights from the Boston Globe Summit 2025 11/20/2025

    Insights from the Boston Globe Summit 2025 exploring biotech funding challenges, AI-driven drug discovery, and genome editing breakthroughs shaping the future of research and care.

  4. Live Insights: 45% Believe The NAMs Industry Should Expand Pre-Competitive Data Sharing Programs 11/13/2025

    According to a recent poll, 45% of participants believe the NAMs industry should expand pre-competitive consortia by sharing validation data and best practices to reduce duplication and accelerate acceptance. Experts Zahar Nahle, Ph.D. and Samantha Atkins, Ph.D. share their insights.

  5. Progressing Precision Medicine Discovery With AI 11/12/2025

    We caught up with Iya Khalil, Ph.D., vice president and head of data, AI, and genome sciences at Merck & Co. to discuss Merck's creation of a foundation model that will help progress precision medicine.

  6. OpenFold3 Released: Redefining The Limits Of Protein Prediction Models 11/4/2025

    OpenFold3, a biomolecular structure prediction model based on AlphaFold3 was recently released by the OpenFold Consortium, a non-profit AI R&D organization.

  7. AI Meets Aging: Inside The Longevity Revolution With Insilico Medicine (Part 2) 9/19/2025

    Part 2 of 2 - An Interview with Alex (Aleksandrs Zavoronkovs) Zhavoronkov, Ph.D. , Longevity and drug discovery researcher, Founder, CEO and CBO at Insilico Medicine.

  8. AI Meets Aging: Inside The Longevity Revolution With Insilico Medicine (Part 1) 9/18/2025

    An Interview with Alex Zhavoronkov, Ph.D. Longevity and drug discovery researcher, Founder, CEO and CBO at Insilico Medicine. Founded in 2014, Insilico Medicine, is one of the earliest AI-driven biotech companies and one of the few who have pipeline drugs in Phase II trials.

  9. From Concept To Confidence: A Collaborative Path To Validating NAMs 8/15/2025

    On August 1, 2025, the Foundation for the National Institutes of Health (FNIH) released a Request for Information (RFI) inviting proposals for pilot projects to accelerate the development, validation, and regulatory acceptance of New Approach Methodologies (NAMs). For drug developers, participating in this process offers not only scientific collaboration but also the potential to co-develop regulatory-grade NAMs aligned with FDA and NIH priorities.

  10. The Rise Of NAMs 7/31/2025

    New Approach Methods (NAMs) are rapidly being accepted as replacements for preclinical animal tests long considered to be the gold standard. NAMs include systems of organoids, organs-on-chips, AI-based prediction models, and non-mammalian species.